142 related articles for article (PubMed ID: 36965015)
1. Bcat1 is controlled by Tsc2/mTORC1 pathway at expression levels and its deficiency together with Bcat2 inactivation suppresses the growth of a Tsc2
Nishikawa K; Mezawa Y; Kobayashi T
Genes Cells; 2023 Jun; 28(6):447-456. PubMed ID: 36965015
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
3. mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency.
Li H; Jin F; Jiang K; Ji S; Wang L; Ni Z; Chen X; Hu Z; Zhang H; Liu Y; Qin Y; Zha X
Oncotarget; 2016 May; 7(19):28435-47. PubMed ID: 27078846
[TBL] [Abstract][Full Text] [Related]
4. mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development.
Peng H; Liu J; Sun Q; Chen R; Wang Y; Duan J; Li C; Li B; Jing Y; Chen X; Mao Q; Xu KF; Walker CL; Li J; Wang J; Zhang H
Oncogene; 2013 Sep; 32(39):4702-11. PubMed ID: 23108404
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
6. Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish.
Kim SH; Kowalski ML; Carson RP; Bridges LR; Ess KC
Dis Model Mech; 2013 Jul; 6(4):925-33. PubMed ID: 23580196
[TBL] [Abstract][Full Text] [Related]
7. Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations.
Aksoylu IS; Martin P; Robert F; Szkop KJ; Redmond NE; Bhattacharyya S; Wang J; Chen S; Beauchamp RL; Nobeli I; Pelletier J; Larsson O; Ramesh V
Mol Autism; 2023 Oct; 14(1):39. PubMed ID: 37880800
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of acid ceramidase contributes to tumor progression in tuberous sclerosis complex.
Astrinidis A; Li C; Zhang EY; Zhao X; Zhao S; Guo M; Olatoke T; Mattam U; Huang R; Zhang AG; Pitstick L; Kopras EJ; Gupta N; Jandarov R; Smith EP; Fugate E; Lindquist D; Markiewski MM; Karbowniczek M; Wikenheiser-Brokamp KA; Setchell KDR; McCormack FX; Xu Y; Yu JJ
JCI Insight; 2023 May; 8(9):. PubMed ID: 36927688
[TBL] [Abstract][Full Text] [Related]
9. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent.
Parkhitko A; Myachina F; Morrison TA; Hindi KM; Auricchio N; Karbowniczek M; Wu JJ; Finkel T; Kwiatkowski DJ; Yu JJ; Henske EP
Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12455-60. PubMed ID: 21746920
[TBL] [Abstract][Full Text] [Related]
10. High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting.
Medvetz D; Sun Y; Li C; Khabibullin D; Balan M; Parkhitko A; Priolo C; Asara JM; Pal S; Yu J; Henske EP
Mol Cancer Res; 2015 Jan; 13(1):50-62. PubMed ID: 25185584
[TBL] [Abstract][Full Text] [Related]
11. Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells.
Li J; Csibi A; Yang S; Hoffman GR; Li C; Zhang E; Yu JJ; Blenis J
Proc Natl Acad Sci U S A; 2015 Jan; 112(1):E21-9. PubMed ID: 25524627
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor β (RARβ).
Liu HJ; Lam HC; Baglini CV; Nijmeh J; Cottrill AA; Chan SY; Henske EP
Oncogene; 2019 Dec; 38(49):7367-7383. PubMed ID: 31420607
[TBL] [Abstract][Full Text] [Related]
13. Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells.
Chen W; Pan Y; Wang S; Liu Y; Chen G; Zhou L; Ni W; Wang A; Lu Y
BMC Cancer; 2017 Jan; 17(1):34. PubMed ID: 28061838
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.
Mrozek EM; Bajaj V; Guo Y; Malinowska IA; Zhang J; Kwiatkowski DJ
PLoS One; 2021; 16(4):e0248380. PubMed ID: 33891611
[TBL] [Abstract][Full Text] [Related]
15. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.
Cao J; Tyburczy ME; Moss J; Darling TN; Widlund HR; Kwiatkowski DJ
J Clin Invest; 2017 Jan; 127(1):349-364. PubMed ID: 27918305
[TBL] [Abstract][Full Text] [Related]
16. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
Huang J; Wu S; Wu CL; Manning BD
Cancer Res; 2009 Aug; 69(15):6107-14. PubMed ID: 19602587
[TBL] [Abstract][Full Text] [Related]
17. Activation of Rheb, but not of mTORC1, impairs spine synapse morphogenesis in tuberous sclerosis complex.
Yasuda S; Sugiura H; Katsurabayashi S; Shimada T; Tanaka H; Takasaki K; Iwasaki K; Kobayashi T; Hino O; Yamagata K
Sci Rep; 2014 Jun; 4():5155. PubMed ID: 24889507
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
[TBL] [Abstract][Full Text] [Related]
19. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
[TBL] [Abstract][Full Text] [Related]
20. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.
Lee PS; Tsang SW; Moses MA; Trayes-Gibson Z; Hsiao LL; Jensen R; Squillace R; Kwiatkowski DJ
Am J Respir Cell Mol Biol; 2010 Feb; 42(2):227-34. PubMed ID: 19395678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
